Trials / Unknown
UnknownNCT04419259
Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea
An Open Label Study to Evaluate the Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Messoud Ashina · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
An exploratory open-label study of rosacea patients to study the efficacy and tolerability of erenumab in the prophylactic treatment of persistent redness and flushing attributed to rosacea. Approximately 30 subjects will be included in the study and receive erenumab 140 mg for three months. The study will begin June 2020 and is expected to last nine months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 334 | 30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8) |
Timeline
- Start date
- 2020-06-09
- Primary completion
- 2021-03-01
- Completion
- 2021-08-01
- First posted
- 2020-06-05
- Last updated
- 2020-06-11
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT04419259. Inclusion in this directory is not an endorsement.